Cardio Dx will sponsor a clinical study investigating use of its PrecisionCHD test to identify patients with CHD and assess response to Agepha's low-dose colchicine agent LODOCO.

The test is used for the detection of antibodies against Borrelia burgdorferi in serum from patients with signs, symptoms, and clinical history consistent with Lyme disease.

The acquired antibodies target hormones like thyroid stimulating hormone, human chorionic gonadotropin, prolactin, and total thyroxine.

NEW YORK – With the recent completion of a multisite study in Europe and the opening of a lab in Tennessee, Glasgow, Scotland-based liquid biopsy developer Dxcover plans to launch its infrared ...

NEW YORK – Diasorin said Wednesday that it has submitted a point-of-care molecular testing system, along with a four-target respiratory panel, for US Food and Drug Administration 510 (k) marketing ...

NEW YORK — Canadian diagnostics developer Nanostics said Thursday that it has received a C$3.8 million (US$2.8 million) grant from Genome Canada and Genome Alberta to boost the adoption of its ...

NEW YORK – After months of declining share prices, diagnostics firm got a reprieve in June as the 360 Top 30 rose nearly 6 percent month over month. The Top 30 mirrored the broader markets as the Dow ...

NEW YORK – With its web-based digital pathology platform, Tribun Health said that its whole-slide image management software offers labs workflow improvements with the ability to integrate its system ...

NEW YORK – Aiforia Technologies, a developer of technologies for pathology using artificial intelligence, said Tuesday that it has received CE-IVD marking for a breast cancer grading test that the ...

NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: 1) Fujirebio Acquires IVD, Life Sciences Materials Firm Plasma Services Group 2) ...

NEW YORK – Barclay's announced Tuesday that it has initiated coverage of Qiagen at Overweight with a price target of $55. The equity research team for life science and diagnostic tools wrote in a note ...

NEW YORK — Gut microbiome health startup 32 Biosciences said Tuesday that it has raised $6 million in private funding, which it said will support the development of its first products. 32 Biosciences ...